12 results about "Premature aging" patented technology

This invention relates to the field of anti-aging drug technology, specifically to the application of small molecule compounds in the preparation of anti-aging drugs. These small molecule compounds competitively block the interaction between KDM6A and the vacuolar ATPase V0 domain subunit ATP6V0C by targeting a specific small molecule binding pocket of the histone demethylase KDM6A, thereby inhibiting the demethylation activity of KDM6A on lysine residue 36 of ATP6V0C. These small molecule compounds can effectively downregulate aging-related β-galactosidase activity, improve cell cycle arrest, and reverse the senescent phenotype of nerve cells induced by the environmental pollutant GenX, making them particularly suitable for combating premature aging of nerve cells induced by perfluorinated and polyfluoroalkyl compounds such as GenX. This technical solution can solve the technical problem of the lack of drugs with clearly defined components, a clear mechanism of action, stable efficacy, and the ability to specifically alleviate aging in existing technologies, and has ideal prospects for widespread application.

The present application provides a kind of transcription factor PpeNAC33 for regulating plant growth and development and chlorophyll degradation, nucleotide sequence is as shown in SEQ.ID.NO.2, amino acid sequence is as shown in SEQ.ID.NO.3.The present application also provides the vector based on the above-mentioned transcription factor, engineering strain.Meanwhile, the application of the above-mentioned transcription factor PpeNAC33 in regulating plant growth and development and chlorophyll degradation is provided.The present application finds a NAC transcriptional regulatory factor PpeNAC33 in the transcriptome analysis of seed abortion peach fruit.Studies have shown that the transcription factor is a key transcription factor for regulating plant growth and development and chlorophyll degradation, and its expression can be accurately regulated by space-time and expression amount, which can be used to realize the accurate control of plant growth process and avoid the occurrence of plant fruit premature aging.

This invention discloses a Polygonatum sibiricum vesicle preparation for treating premature ovarian failure, its preparation method, and its application. The preparation method includes: cleaning Polygonatum sibiricum, juicing, filtering to remove residue, and collecting the juice; subjecting the juice to gradient centrifugation to remove residual plant tissue, plant cells, and plant cell debris; then using an extraction reagent for stepwise precipitation, collecting the precipitate, and resuspending it to obtain the final product. The Polygonatum sibiricum vesicle preparation prepared by this invention can be efficiently taken up by ovarian granulosa cells. It effectively treats premature ovarian failure by activating the Nrf2 signaling pathway, upregulating antioxidant enzyme expression, scavenging reactive oxygen species, restoring mitochondrial membrane potential, inhibiting apoptosis, and restoring the expression levels of estrogen, follicle-stimulating hormone, and anti-Müllerian hormone. The preparation method of this invention is standardized, biocompatible, and safe, and has broad clinical application prospects.

The application relates to a method for establishing an early ovarian failure rat model, which comprises the following steps: taking healthy rats, and performing gavage on the rats according to a dosage of 10-20 mg / Kg of a phytostilbene preparation, wherein the dosage is the ratio of phytostilbene to the weight of the rats, and obtaining the early ovarian failure rat model after four days of administration. The early ovarian failure rat model is obtained by performing gavage on the rats after the phytostilbene preparation, the model is simple to establish, and the model establishment time is short. Through ovarian pathological observation, it can be seen that the simulated animal model has obvious ovary tissue damage, follicular granulosa cell destruction and apoptosis, and follicle atresia and other symptoms. The obtained model has good stability and repeatability. The phytostilbene is used to successfully establish the early ovarian failure rat model, lays a good foundation for establishing a stable early ovarian failure model for basic research, and provides a reliable method for the construction of the early ovarian failure model.

Leaf development, especially in leafy greens, is crucial for crop productivity. In various plants, DA1, a pivotal ubiquitin receptor that negatively regulates leaf growth, and EOD1 (ENHANCER1 OF DA1), an E3 ubiquitin ligases that interacts with DA1 through its RING domain, influence organ size. In this disclosure, in lettuce (Lactuca sativa), homologs genes were identified for both DA1 and EOD1, and da1 single mutants, da1 / eod1 double mutants, and DA1 overexpressing lines (DA1ox) were created. The da1 / eod1 double mutant exhibited a striking phenotype with larger organ size, accelerated growth, and increased biomass, resulting in higher yields and rapid growth traits pivotal for Controlled Environment Agriculture (CEA). Additionally, the da1 / eod1 double mutant displayed a pronounced ‘stay-green’ phenotype, characterized by elevated chlorophyll b levels, which implies extended shelf life, and enhanced postharvest quality, both traits indispensable for leafy vegetables in CEA settings. In contrast, the DA1ox line exhibited early senescence and diminished organ size. Based on these findings that spotlight the nuanced roles of the DA1-EOD1 module in modulating plant growth phases and its potential to revolutionize breeding strategies for improved yield and postharvest longevity in CEA-cultivated leafy greens, this disclosure provides guide RNAs for gene editing of DA1 and EOD1, and transformed lettuce having improved organ size and postharvest quality.

The application provides application of PWWP3B in preparation of a diagnostic product and a therapeutic drug for testicular premature failure or oligoasthenospermia, and finds that the occurrence of testicular premature failure or oligoasthenospermia is related to abnormal PWWP3B gene or abnormal expression level of a PWWP3B gene coding protein. Therefore, testicular premature failure or oligoasthenospermia can be definitely diagnosed by detecting the PWWP3B gene sequence or the PWWP3B protein expression level. Meanwhile, it is found that a mutation pathogenic gene related to testicular premature failure or oligoasthenospermia contains 7 mutation sites, and based on the above 7 mutation points, a corresponding AAV carrier is constructed for treatment, and the effectiveness of a gene therapy drug for a specific genetic mutation is confirmed.

This invention discloses a mixed cell preparation and its application in the preparation of drugs for treating premature ovarian failure. The mixed cell preparation comprises granulosa cells and mesenchymal stem cells, mixed in a certain ratio (preferably 1:1). Granulosa cells are obtained by inducing differentiation from mesenchymal stem cells and express granulosa cell-specific markers (FOXL2, FSHR, etc.), participating in follicular structure reconstruction; mesenchymal stem cells can improve the ovarian microenvironment, inhibit inflammation, and resist fibrosis, providing a suitable "soil" for the survival of granulosa cells. In vitro experiments are expected to show that mixed culture can significantly increase estradiol secretion levels and cell survival rate. Animal models of premature ovarian failure are expected to show that mixed cell therapy can significantly restore the estrous cycle, improve hormone levels, increase the number of follicles at all stages, and improve pregnancy rates, with effects significantly superior to single-cell therapy. This invention utilizes the synergistic effect of the two cell types to achieve dual repair of the "seed" and the "soil," providing a novel treatment strategy for premature ovarian failure.

This invention belongs to the field of animal model technology, specifically relating to a method for constructing an animal model of aplastic anemia and premature ovarian failure (POF) and its application in mesenchymal stem cell therapy. Busulfan and cyclophosphamide were administered intraperitoneally to the animals six times in the following order: first, busulfan was administered three times consecutively, followed by cyclophosphamide three times consecutively, thus establishing an animal model of the dual pathological state of aplastic anemia and POF. Furthermore, based on this animal model, a mesenchymal stem cell therapy based on disease stages was established, achieving significant recovery of ovarian function and providing a reliable technical foundation for clinical translational research on POF in adolescents.

The application provides application of breast milk-derived stem cells combined with umbilical cord mesenchymal stem cells in preparation of a drug for treating premature ovarian failure, and belongs to the technical field of biological medicine. The application also provides a stem cell preparation for treating premature ovarian failure, which comprises breast milk-derived stem cells, umbilical cord mesenchymal stem cells, resveratrol glycoside, melatonin, Leonurus japonicus glycoside, vitamin C, human blood albumin and physiological saline. The breast milk-derived stem cells and the umbilical cord mesenchymal stem cells play a core role, promote follicle survival and regeneration, and improve the pathological state of ovarian ischemia and hypoxia; the Leonurus japonicus glycoside can assist in dredging and improving local microcirculation; the vitamin C, the melatonin and the resveratrol glycoside can remove excessive harmful free radicals in the ovary and the whole body, and curb the continuous damage of oxidative stress to the follicle. Animal experiments show that the stem cell preparation can significantly improve the serum hormone level of premature ovarian failure mice, increase the reserve and competence of follicles at all levels, and has a clear repairing effect on ovarian function.

This invention discloses an antibody for prolonging ovarian function, a culture medium, a method for inhibiting primordial follicle activation, and its application. The antibody is a CD138 antibody. In the technical solution provided by this invention, the CD138 antibody can precisely regulate the transition rhythm of primordial follicles from a quiescent state to a developing state by targeting and inhibiting the primordial follicle activation signaling pathway. This regulatory mechanism can reduce the ineffective activation and loss of follicles in early reproductive years, allowing more primordial follicles to remain dormant, thereby prolonging the physiological lifespan of the follicle pool. This provides biological protection for the even distribution of reproductive cell resources throughout the reproductive cycle in female individuals, effectively avoiding the risk of infertility or premature ovarian failure caused by premature follicle depletion.

The application discloses a polypeptide UPCP and application thereof in preparation of anti-aging products. The polypeptide UPCP provided by the application has an amino acid sequence of sequence 4 in the sequence list. The polypeptide is applied in preparation of products with any one of the following functions: 1) treating children's premature aging; 2) delaying physiological aging of mammals or cells thereof; 3) improving premature aging of mammals; the improvement of premature aging of mammals is embodied in delaying premature aging of mammals; 4) improving body weight of premature aging animals; the improvement of body weight of premature aging animals is embodied in increasing body weight of premature aging animals; 5) relieving motor dysfunction of premature aging animals; 6) prolonging survival period of premature aging animals, etc. The application develops a specific peptide (UPCP) which can inhibit HGPS cell aging, improve aging characteristics of HGPS premature aging mice and prolong survival period, and provides a new strategy for treatment of HGPS.